Fertilo In Vitro Research Study and Trial
Part of paid clinical trials in Clovis, California.
- Sponsor
- Gameto, Inc.
- Study ID
- NCT06858111
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- In Vitro Maturation of Oocytes
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 35 Years
- Healthy Volunteers
- Accepted
Interventions
- Fertilo — BIOLOGICALFertilo is an engineered line of ovarian support cells that aid egg maturation.
- Medicult IVM — DEVICEMediCult IVM is a system of culture media designed for the in vitro maturation of immature oocytes.
Study Details
The goal of this clinical trial is to evaluate the safety and efficacy of using Fertilo for In vitro maturation (IVM) in participants 18-35 years of age. The main question it aims to answer is whether the use of Fertilo is superior to using Medicult IVM for In vitro maturation. Researchers will compare the number of ongoing pregnancies at 12 weeks gestation for participants in each arm. * Arm 1 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Fertilo for 30 hours. * Arm 2 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Medicult IVM for 30 hours.
Key Dates
- Start date
- Apr 17, 2025
- Status verified
- Jun 2026
- Primary completion
- May 31, 2027
- Completion
- Jan 31, 2028
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: FertiloImmature cumulus-oocyte complexes (COCs) are oocytes surrounded by cumulus cells that have not yet matured. The COCs are cultured in Fertilo coculture condition then fertilized, grown to the blastocyst stage, vitrified, and later transferred for reproductive purpose.
- Active Comparator: Medicult IVM®Immature COCs are cultured in the standard IVM system MediCult IVM® then fertilized, grown to the blastocyst stage, vitrified, and later transferred for reproductive purpose.
Primary Outcome Measure
Demonstration of the superiority of Fertilo compared to the currently approved MediCult IVM® for infertility treatment via IVF procedures. [ Time Frame: 12 weeks gestation ]
Central Contacts
- Clinical Trials512-535-1164
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Women's Specialty & Fertility Center | Clovis | California | 93611 | Carlos Sueldo, MD (PRINCIPAL_INVESTIGATOR) |
| HRC Fertility | Encino | California | 91436 | Robert Boostanfar, MD (PRINCIPAL_INVESTIGATOR) |
| Florida Fertility Institute | Clearwater | Florida | 33759 | Mark Sanchez, MD (PRINCIPAL_INVESTIGATOR) |
| IVF Florida | Pembroke Pines | Florida | 33026 | Luis Hoyos, MD (PRINCIPAL_INVESTIGATOR) |
| Shady Grove Fertility | Rockville | Maryland | 20850 | Kate Devine, MD (PRINCIPAL_INVESTIGATOR) |
| Columbia University Fertility Center | New York | New York | 10019 | Eric Forman, MD (PRINCIPAL_INVESTIGATOR) |
| Reach Fertility | Charlotte | North Carolina | 28207 | Jack Crain, MD (PRINCIPAL_INVESTIGATOR) |
| Conceptions Fertility | Raleigh | North Carolina | 27607 | John Park, MD (PRINCIPAL_INVESTIGATOR) |
| Care Fertility | Bedford | Texas | 76022 | Charlene Nwajei Kevin Doody, MD (PRINCIPAL_INVESTIGATOR) |
| Dallas Fort Worth Fertility Associates | Dallas | Texas | 75231 | Samuel Chantilis, MD (PRINCIPAL_INVESTIGATOR) |
| Aspire Fertility San Antonio | San Antonio | Texas | 78528 | Jennifer Knudtson, MD (PRINCIPAL_INVESTIGATOR) |
| Shady Grove Houston | Webster | Texas | 77598 | Vicki Schnell, MD (PRINCIPAL_INVESTIGATOR) |
| Utah Fertility Center | Pleasant Grove | Utah | 84062 | Shawn Gurtcheff, MD (PRINCIPAL_INVESTIGATOR) |